Robust clinical evidence supports the inclusion of agents such as semaglutide and liraglutide for reducing HbA1c levels, achieving substantial weight loss, and mitigating complications associated with T2DM and obesity (16)(39)
However, after stimulation with 20mM glucose, somatostatin knockout mice had increased plasma insulin and glucagon levels
[] Furthermore, the two novel agents retatrutide and orforglipron are in phase II clinical studies, [] and tirzepatide is in phase III human trials to determine the safety and efficacy for chronic management of over-weight in diabetic patients
Regular medical check-ups are essential to monitor response and catch any issues early
While Ozempic is primarily used to help manage blood sugar levels in people with type 2 diabetes, it has been shown to promote weight loss as a secondary effect
Interestingly enough, patients with higher baseline ASCVD risk with tirzepatide therapy showed significantly more reductions in risk [3]